title: Cholera toxin directly enhances IL-17A production from human CD4+ T cells.
abstract: The significance of Th17 cells and IL-17A signaling in host defense and disease development has been demonstrated in various infection and autoimmune models. Additionally, the generation of Th17 cells is highly influenced by microbes. However, the specific bacterial components capable of shaping Th17 responses have not been well defined. The goals of this study were to understand how a bacterial toxin, cholera toxin (CT), modulates Th17-dominated response in isolated human CD4(+) T cells, and what are the mechanisms associated with this modulation. CD4(+) cells isolated from human peripheral blood were treated with CT. The levels of cytokine production and specific Th cell responses were determined by ELISA, Luminex assay, and flow cytometry. Along with the decreased production of other proinflammatory cytokines (IFN-γ, TNF-α, and IL-2), we found that CT could directly enhance the IL-17A production through a cAMP-dependent pathway. This enhancement is specific for IL-17A but not for IL-17F, IL-22, and CCL20. Interestingly, CT could increase IL-17A production only from Th17-committed cells, such as CCR6(+)CD4(+) T cells and in vitro-differentiated Th17 cells. Furthermore, we also demonstrated that this direct effect occurs at a transcriptional level because CT stimulates the reporter activity in Jurkat and primary CD4(+) T cells transfected with the IL-17A promoter-reporter construct. This study shows that CT has the capacity to directly shape Th17 responses in the absence of APCs. Our findings highlight the potentials of bacterial toxins in the regulation of human Th17 responses.
authors.affiliation: Center for Comparative Respiratory Biology and Medicine, University of California, Davis, Davis, CA 95616.
authors.forename: Hsing-Chuan
authors.initials: HC
authors.lastname: Tsai
authors.forename: Reen
authors.initials: R
authors.lastname: Wu
mesh_terms: D002478:Cells, Cultured; D054418:Chemokine CCL20 / Q000378:metabolism; D002772:Cholera Toxin / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D020381:Interleukin-17 / Q000096:biosynthesis* / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D054399:Receptors, CCR6 / Q000378:metabolism; D015398:Signal Transduction; D058504:Th17 Cells / Q000276:immunology / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000097043:Interleukin-22
chemical_list: D054418:Chemokine CCL20; D002772:Cholera Toxin; D000242:Cyclic AMP; D007371:Interferon-gamma; D020381:Interleukin-17; D007376:Interleukin-2; D007378:Interleukins; D054399:Receptors, CCR6; D014409:Tumor Necrosis Factor-alpha; D000097043:Interleukin-22; C108355:CCL20 protein, human; C106311:CCR6 protein, human; C508717:IL17A protein, human; C440021:IL17F protein, human
references.citation: Curr Opin Immunol. 2011 Oct;23(5):613-9
references.pmid: 21852080
references.citation: Nat Rev Immunol. 2008 May;8(5):337-48
references.pmid: 18408735
references.citation: J Exp Med. 2009 Mar 16;206(3):535-48
references.pmid: 19273625
references.citation: Nat Med. 2009 Jun;15(6):633-40
references.pmid: 19465928
references.citation: Immunity. 2010 May 28;32(5):692-702
references.pmid: 20434372
references.citation: Nat Immunol. 2011 Jun;12(6):568-75
references.pmid: 21516111
references.citation: J Exp Med. 2008 May 12;205(5):1063-75
references.pmid: 18411338
references.citation: J Immunol. 2008 Jan 1;180(1):214-21
references.pmid: 18097022
references.citation: J Immunol. 2007 Jun 15;178(12):8138-47
references.pmid: 17548652
references.citation: J Immunol. 2009 Aug 1;183(3):1598-606
references.pmid: 19592658
references.citation: J Leukoc Biol. 2000 Oct;68(4):568-74
references.pmid: 11037980
references.citation: Int J Biochem Cell Biol. 2007;39(10):1771-5
references.pmid: 17716938
references.citation: Nat Immunol. 2011 Jun;12(6):521-2
references.pmid: 21587311
references.citation: J Immunol. 2012 Oct 1;189(7):3285-91
references.pmid: 22997231
references.citation: Clin Exp Immunol. 2000 Aug;121(2):283-8
references.pmid: 10931143
references.citation: Nat Immunol. 2007 Sep;8(9):950-7
references.pmid: 17676044
references.citation: Int J Pediatr Otorhinolaryngol. 2002 May 15;63(3):235-41
references.pmid: 11997159
references.citation: Nat Immunol. 2011 Oct 16;12(12):1238-45
references.pmid: 22001828
references.citation: J Biol Chem. 2008 Jun 20;283(25):17003-8
references.pmid: 18434325
references.citation: J Exp Med. 1999 Feb 1;189(3):541-52
references.pmid: 9927516
references.citation: Inflamm Bowel Dis. 2011 Jun;17(6):1343-58
references.pmid: 21305677
references.citation: Immunity. 2009 Jan 16;30(1):92-107
references.pmid: 19119024
references.citation: Infect Immun. 2002 Oct;70(10):5533-9
references.pmid: 12228279
references.citation: J Exp Med. 2007 Aug 6;204(8):1849-61
references.pmid: 17635957
references.citation: Eur J Immunol. 2009 May;39(5):1221-30
references.pmid: 19350551
references.citation: Exp Cell Res. 2011 Mar 10;317(5):620-31
references.pmid: 21376175
references.citation: Trends Immunol. 2002 Mar;23(3):144-50
references.pmid: 11864843
references.citation: Mol Immunol. 2009 Nov;47(1):3-7
references.pmid: 19193443
references.citation: J Leukoc Biol. 2006 Oct;80(4):880-8
references.pmid: 16888088
references.citation: Eur J Immunol. 2009 Mar;39(3):658-61
references.pmid: 19283717
references.citation: J Exp Med. 1990 Jul 1;172(1):95-103
references.pmid: 2162906
references.citation: J Med Virol. 2002 Mar;66(3):320-8
references.pmid: 11793383
references.citation: Nat Immunol. 2002 Nov;3(11):1033-40
references.pmid: 12407412
references.citation: J Exp Med. 1993 Oct 1;178(4):1309-20
references.pmid: 8376936
references.citation: Adv Exp Med Biol. 1995;371B:1501-6
references.pmid: 7502845
references.citation: J Exp Med. 2007 Nov 26;204(12):2803-12
references.pmid: 18025126
references.citation: Nature. 2009 Jul 16;460(7253):405-9
references.pmid: 19578362
references.citation: Nat Immunol. 2011 Jun 26;12(8):796-803
references.pmid: 21706005
references.citation: Infect Immun. 2011 Mar;79(3):1300-10
references.pmid: 21149590
references.citation: Proc Natl Acad Sci U S A. 1986 Aug;83(15):5673-7
references.pmid: 3016713
references.citation: Clin Immunol. 2009 Jun;131(3):385-94
references.pmid: 19307156
references.citation: Arthritis Rheum. 2007 Aug;56(8):2608-19
references.pmid: 17665454
references.citation: Eur J Immunol. 2010 Jan;40(1):153-61
references.pmid: 19830735
references.citation: J Biol Chem. 2011 Dec 16;286(50):43437-46
references.pmid: 22025620
references.citation: Immunol Invest. 1999 Sep-Dec;28(5-6):339-46
references.pmid: 10574631
references.citation: Nat Immunol. 2011 Jun;12(6):560-7
references.pmid: 21516112
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2480-5
references.pmid: 21262800
references.citation: PLoS One. 2009;4(4):e5190
references.pmid: 19360100
references.citation: J Immunol. 1988 Nov 15;141(10):3429-37
references.pmid: 2846687
references.citation: Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10638-43
references.pmid: 20479237
references.citation: Cell. 2006 Sep 22;126(6):1121-33
references.pmid: 16990136